Irati Garmendia

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Esther Redín, Irati Garmendia, Teresa Lozano et al. · Journal for ImmunoTherapy of Cancer · 2021 · 88 citations · Full text

YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib

Irati Garmendia, María J. Pajares, Francisco Hermida‐Prado et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 68 citations · Full text

The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer

Elena Martínez‐Terroba, Teresa Ezponda, Cristina Bértolo et al. · Laboratory Investigation · 2018 · 63 citations · Full text

Tumor Biology, Oncogenic Agent, Medicine +7

PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas

Mario Sánchez‐Canteli, Rocío Granda‐Díaz, Nagore del Rio-Ibisate et al. · Cancer Immunology Immunotherapy · 2020 · 58 citations · Full text

Cancer Immunosurveillance, Medicine, Immunology +13

The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042

Francisco Hermida‐Prado, M. Ángeles Villaronga, Rocío Granda‐Díaz et al. · Journal of Clinical Medicine · 2019 · 24 citations · Full text

Chemoprevention Strategy, Treatment Resistance, Tumor Biology +17